晚期转移性黑色素瘤患者生存:新型治疗的影响——2017年更新
该探索性分析数字化25项试验的83条Kaplan-Meier生存曲线,按治疗策略和线数分组加权平均生成PFS和OS曲线。BRAF联合MEK抑制在激酶抑制剂中PFS和OS最有利;PD-1联合CTLA-4抑制在免疫检查点抑制剂中除一线OS外生存最佳。前6个月BRAF联合MEK抑制优于检查点阻断,之后PD-1单药或联合CTLA-4阻断更优。
要点
- 激酶抑制剂中,BRAF联合MEK抑制在所有治疗线的PFS和OS最有利。
- 免疫检查点抑制剂中,PD-1联合CTLA-4抑制除一线OS外生存结局最佳。
- 前6个月BRAF联合MEK抑制更优,之后PD-1单药或联合CTLA-4更优。
核心结论
- 激酶抑制剂中BRAF联合MEK抑制在所有治疗线的PFS和OS最有利;免疫检查点抑制剂中PD-1联合CTLA-4抑制除一线OS外生存结局最佳。
- 前6个月BRAF联合MEK抑制优于检查点阻断,之后PD-1单药或联合CTLA-4阻断更优。
- 上述结果需前瞻性临床试验确认。
研究设计与样本
- 探索性分析,数字化25项试验的83条Kaplan-Meier生存曲线,按治疗策略和治疗线分组。
- 对每组通过加权平均生成PFS和OS的平均生存曲线。
主要发现
- 按治疗策略分组的生存曲线高度一致,尤其在一线设置。
- 激酶抑制剂中,BRAF联合MEK抑制在所有治疗线的PFS和OS最有利。
- 免疫检查点抑制剂中,PD-1联合CTLA-4抑制除一线OS外所有类别生存结局最佳;一线OS与PD-1单药抑制相似。
- 前6个月内BRAF联合MEK抑制优于检查点阻断,之后PD-1单药或联合CTLA-4阻断更优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 两种策略尚无前瞻性头对头比较研究结果。
- 结果为探索性分析,需前瞻性临床试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of metastatic melanoma is still undergoing a process of major change. The two most important novel therapeutic strategies, selective kinase inhibitors and immune checkpoint blockers, both significantly prolong survival times of patients with advanced metastatic disease. Different agents, dose regimens and combinations have been tested against each other vigorously within these two groups. However, results from prospective head-to-head comparative studies of both strategies are still lacking. We performed an exploratory analysis of survival data from selected clinical trials representative for the new treatment strategies in advanced metastatic melanoma. Eighty-three Kaplan-Meier survival curves from 25 trials were digitised and grouped by therapeutic strategy and treatment line. For each of these groups, mean survival curves were generated for progression-free (PFS) and overall survival (OS) by weighted averaging. Survival curves grouped together by therapeutic strategy revealed a high concordance, particularly in the first-line setting. For kinase inhibitors, the most favourable PFS and OS in all therapy lines were observed for combined BRAF plus MEK inhibition. For immune checkpoint inhibitors, combined PD-1 plus CTLA-4 inhibition demonstrated the best survival outcome in all categories except for OS in first-line therapy. For the latter, combined PD-1 plus CTLA-4 inhibition showed similar outcomes as single-agent PD-1 inhibition. Comparison of kinase inhibitors and checkpoint blockers revealed a superiority of combined BRAF plus MEK inhibition within the first 6 months, later changing to a superiority of PD-1 blockers alone or in combination with CTLA-4 blockers. These results need confirmation by prospective clinical trials.
引用
- Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017. PMID: 28756137. doi:10.1016/j.ejca.2017.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。